SCHEMBL20215949

SCHEMBL20215949

CC(C)(C)OC(=O)NC(c1ccc(Cl)cc1)[C@@H](N)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.44
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
S1PR3 Q99500 2/20 0.41
GAA P10253 2/20 0.41
P2RY2 P41231 1/20 0.40
LMNA P02545 2/20 0.39
CACNA1B Q00975 1/20 0.39
TSHR P16473 1/20 0.39
PRCP P42785 3/20 0.39
CYP3A4 P08684 2/20 0.39
NFKB1 P19838 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1699081 1.00 TRPA1 (0.44) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL27131683 1.00 TRPA1 (0.44) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL27033158 1.00 TRPA1 (0.44) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL21323896 1.00 TRPA1 (0.44) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL17302050 0.94 CNR1 (0.41) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL17302197 0.94 CNR1 (0.41) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL17302118 0.89 S1PR3 (0.48) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL17301887 0.86 S1PR3 (0.46) TRPA1PPARGPPARAALDH1A1MAPT
SCHEMBL28696589 0.85 CTSK (0.51) PPARGPPARAMAPTCTSSCTSK
SCHEMBL28598937 0.85 CTSK (0.51) PPARGPPARAMAPTCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190270726-A1 PRODUCTS OF CHIRAL SYNTHESIS OF CIS-IMIDAZOLINE COMPOUNDS AND THEIR USE UNITY BIOTECHNOLOGY, INC. 2019-09-05 US disclosed
US-10329279-B2 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use UNITY BIOTECHNOLOGY, INC. (US) 2019-06-25 US disclosed
US-9988368-B1 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use UNITY BIOTECHNOLOGY, INC. (US) 2018-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329279-B2 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use MDM2, CDKN1A, TP53 TRPA1 2931/4885PPARG 2113/4885PPARA 1538/4885
US-20190270726-A1 PRODUCTS OF CHIRAL SYNTHESIS OF CIS-IMIDAZOLINE COMPOUNDS AND THEIR USE MDM2, CDKN1A, TP53 TRPA1 2728/4885PPARG 2025/4885PPARA 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.